RxDoctor Payments DataLook up a doctor →

Peter Hennis

Gerontology · Casa Grande, AZNPI 1588233175

Payments from drug & device makers

$63,278in general payments, 2019–2025

Across 997 payments — averaging $63.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$40K
  • UCB, Inc.$9K
  • AbbVie$4K
  • AstraZeneca$3K
  • Johnson & Johnson$2K
  • Mallinckrodt Hospital Products Inc.$1K
  • plus $5K from 27 others

What the payments were for

  • Consulting fees$5,0808%
  • Speaking & faculty fees$33,60053%
  • Travel & lodging$4,9478%
  • Food & beverage$19,49331%
  • Education$1580%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,278 in reported general payments places this provider in the 95th percentile of 99 gerontology providers in Arizona.

See all gerontology providers in Arizona

Medicare billing

Part B allowed, 2024
$64,230
Medicare patients
205
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase25$1,436,801
Humira(Cf) PenAdalimumab35$275,726
BenlystaBelimumab37$174,088
Xeljanz XrTofacitinib Citrate27$162,900
Enbrel MiniEtanercept15$134,573
Cyltezo(Cf) PenAdalimumab-Adbm14$106,808
SaphneloAnifrolumab-Fnia20$103,268
Cimzia (2 Pack)Certolizumab Pegol15$86,251
KevzaraSarilumab13$55,966
Hydroxychloroquine Sulfate205$10,022
Mycophenolate Mofetil104$9,342
MethotrexateMethotrexate Sodium239$6,367
Colchicine44$2,842
Prednisone280$1,830
Duloxetine Hcl33$1,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$39,584$1,436,80125 claims
GSKBenlysta$513$174,08837 claims
AstraZenecaSaphnelo$3,048$103,26820 claims
UCB, Inc.Cimzia (2 Pack)$9,066$86,25115 claims
SanofiKevzara$427$55,96613 claims
Fresenius Kabi USA, LLCSodium Chloride$97$3416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 99 gerontology providers in Arizona.

Other gerontology in Casa Grande

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →